GlycoNex (ROCO:4168) Total Liabilities: NT$571.88 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4168 GlycoNex Inc ROCO:4168
56 GF Score
Price NT$23.45
GF Value NT$75.41
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is GlycoNex Total Liabilities?

GlycoNex ROCO:4168 -2.09% 56 Total Liabilities is NT$571.88 Mil as of Dec. 2025. GuruFocus rates ROCO:4168 with a GF Score™ of 56/100 and a GF Value™ of NT$75.41 (Significantly Undervalued). The stock has 2 warning signs investors should review.

GlycoNex's Total Liabilities for the quarter that ended in Dec. 2025 was NT$571.88 Mil.

GlycoNex's quarterly Total Liabilities increased from Jun. 2025 (NT$281.65 Mil) to Sep. 2025 (NT$542.22 Mil) and increased from Sep. 2025 (NT$542.22 Mil) to Dec. 2025 (NT$571.88 Mil).

GlycoNex's annual Total Liabilities declined from Dec. 2023 (NT$276.40 Mil) to Dec. 2024 (NT$270.01 Mil) but then increased from Dec. 2024 (NT$270.01 Mil) to Dec. 2025 (NT$571.88 Mil).

GlycoNex Total Liabilities Historical Data

* Premium members only.

The historical data trend for GlycoNex's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlycoNex Total Liabilities Chart

GlycoNex Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 36.07 271.34 276.40 270.01 571.88

GlycoNex Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 270.01 293.29 281.65 542.22 571.88
ROCO:4168
56GF Score
GlycoNex Inc ROCO:4168
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GlycoNex Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

GlycoNex's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=93.493+(473.564+4.818
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=571.88

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1554.223-982.348
=571.88

GlycoNex's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=93.493+(473.564+4.818
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=571.88

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=1554.223-982.348
=571.88

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of NT$571.88 Mil mean?
GlycoNex (ROCO:4168) has a Total Liabilities of NT$571.88 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for GlycoNex and its competitors.
Is GlycoNex's Total Liabilities too high?
GlycoNex's current Total Liabilities is NT$571.88 Mil. Overall, GlycoNex has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GlycoNex's Total Liabilities compare to VRTX and REGN?
GlycoNex's Total Liabilities of NT$571.88 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for GlycoNex and its competitors. GlycoNex's current Total Liabilities is NT$571.88 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GlycoNex stock overvalued right now?
Based on GuruFocus' analysis, GlycoNex (ROCO:4168) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$75.41, compared to a current price of NT$23.45 — trading 68.9% below its estimated fair value. The current Total Liabilities is NT$571.88 Mil. GlycoNex's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For GlycoNex (ROCO:4168), the current Total Liabilities is NT$571.88 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GlycoNex (ROCO:4168) Overvalued in 2026?

Based on GuruFocus' analysis, GlycoNex stock appears to be undervalued. The current stock price of NT$23.45 is trading 68.9% below its estimated GF Value™ of NT$75.41. GuruFocus considers GlycoNex to be Significantly Undervalued.

Key valuation signals for ROCO:4168:

  • Total Liabilities: NT$571.88 Mil
  • GF Value™: NT$75.41 vs. price of NT$23.45 (68.9% below fair value)
  • GF Score™: 56/100 with 2 warning signs

No single metric tells the full story. See the ROCO:4168 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GlycoNex Business Description

Address Section 1, Xintai 5th Road, 8th Floor, No. 97, Xizhi District, New Taipei City, TWN, 221
GlycoNex Inc is a Taiwan-based company engaged in the development of cancer drugs from the combination of glycosphingolipid antigen and human monoclonal antibody technologies. It has a panel of antibodies that targets various carbohydrate antigens. The antibodies are cloned from hybridoma, engineered to improve stability, and can serve as reagents with applications that include ELISA, Western blot, flow cytometry, and TLC immunostaining. The other services provided by the firm include functional evaluation, antibody research, and antibody engineering. It has two reportable segments: antibody new drug, which derives maximum revenue, and exclusive investment. Geographically, the group derives maximum revenue from Taiwan and the rest from Japan.
56GF Score

Get the complete analysis for ROCO:4168

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$23.45
Price
NT$75.41
GF Value